Evidence that the c-erbB-2 proto-oncogene is important in prognosis and oncogenesis in a number of human malignancies is increasing. DNA (Southern) hybridization and immunoblotting (Western) techniques arc most commonly utilized to determine the amplification and protein expression of this proto-oncogene, respectively. These extraction techniques are often time consuming, costly, and subject to variability depending on the histological characteristics of the tumor. Immunohistochemistry (MC), on the other hand, is more often time and cost effective. In addition, M C may offer enhanced sensitivity over extraction techniques because of the in situ nature of analysis. In data presented here, 71 cases of human mammary carcinoma were concomitantly assessed for c-erbB-2 gene copy number and oncoprotein expression by dilution DNA hybridization and M C , respectively. In 65 (92%) of 71 cases, high-level expression was associated with gene amplification, whmas moderate or lowlevel expression was associated with a normal diploid gene copy number. In five of the six discrepant cases, M C predicted amplification which was not comborated by South-Literature Cited Ali I. Campbell G, Lidereau R, Callahan R (1988): Amplification of c-er&?-2 and aggressive human breast tumors? Science 240:1795 Barnes D, Lammie G. Millis R, Gullick W (1988): An immunohistochemical evaluation ofc-erbB-2 expression in human breast carcinoma. Br J Cancer 58:448 N (1988): Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grade. Cancer Res 48:1238 Cline M. Battifora H. Yokata J (1987): Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol 7999
Introduction
The c-erbB-2 proto-oncogene was initially identified by transfection studies in which NIH/3T3 cells were transformed with genomic DNA from chemically induced rat neuroblastomas (Shih et al., 1981) . The responsible gene encodes for a v-erbB-like protein that has an extracellular, a transmembrane, and an intracellular domain (Schechter et al., 1984) . The homologue c-erbB-2 (Her-2Ineu) is overexpressed in many tumors. Evidence is presently accumulating that amplification of the c-er&-2 proto-oncogene is an important prognostic indicator in a number of malignancies (King et al., 1989; Tindon et al., 1989; Tsuda et al., 1989; Berger et al., 1988; Cline et al., 1987; Slamon et al., 1987; Zhou et al., 1987) , and may possibly be involved in neoplastic initiation (Semba et al., 1985; Venter et al., 1987) . Overexpression of the c-erbB-2 oncoprotein, without amplification of c-erbB-2 gene copy number, may be an alterative ' Correspondence to: Billie-Jo Kerns, Box 3873, Department of Surgery, Duke University Medical Center, Durham, NC 27710. ern analysis. In these cases, tumor m a s was limited by the intraductal component of the lesion or by an abundance of stromal elements within the specimen. In 39 of the 71 total cases, Western immunoblotting was compared with M C in the assessment of oncoprotein expression. Concordance was found in 33 (85%) of 39 cases. In four of the six discrepant cases, high levels of c-erbB-2 expression were demonstrated by M C but not by immunoblotting. In thesc cases, intraductal disease and stroma-rich tumors again led to a relative paucity of neoplastic tissue within the specimens. We condude that M C o&s a favorable alternative to either Southcm analgene copy number and expression levels of oncoprotein in human mammary carcinoma. Furthermore, M C may prove advantageous to either extraction technique in specimens with limited tumor mas, such as biopsy materials, stromarich tumors, or early stage lesions such as intraductal carcinoma. (J Histochem Cyrochun 389823-1830, 1990 ) KEY WORDS: c-e&-2; Immunohistochemistry; Expression; Breast cancer. ysis OK Westem immunoblotthg in the " t Of c-ubs-2 means to activate this proto-oncogene (Lacroix et al.. 1989; Tindon et al., 1989; Berger et al., 1988; Kraus et al., 1987) .
DNA hybridization, used for determining the presence of gene amplification, is tissue quality dependent, time consuming, and more expensive than immunohistochemistry (IHC). The Western immunoblot technique for determination of protein expression is subject to variable results and may be less sensitive, especially in cases of intraductal tumors or tumors with abundant stroma (Slamon et al., 1989). To be clinically useful, an easier and more dependable technique needs to be available. IHC has been used by a number >f groups as a way of detecting the c-er&-2 protooncogene protein product (Wright et al., 1989; Barnes et al., 1988; van de Vijver et al., 1988) . To date, IHC has not been standardized for the c-erbB-2 protein product (Thor et al., 1989) , nor systematically compared to other contemporary research methodologies for determining c-erbB-2 expression. To this end, we compared an immunohistochemical technique for analysis of c-erbB-2 in breast cancer with simultaneous determination of the protein expression by Western immunoblot and gene content by dilution DNA hybridization.
Materials and Methods
Tirma. Breast tumor specimens were obtained from patients at the Duke University Medical Center Breast Clinic between 1987 and 1988. At the time of surgical biopsy or resection. samples were examined grossly by a surgical pathologist for tumor infiltration, and tumor-bearing tissue was flash-frozen in liquid nitrogen. Samples were stored at -135% until usayed.
Primyy Antibodies. The monoclonal antibody (MAb) uxd in this study ( l i b #?>I) was a gift from Beatrice Langton (Triton Biosciences: Alameda. CA), and was diluted 1:50 in PBS, pH 7.4, containing 2% bovine serum albumin (BSA). This antibody specifically reacts with the extracellular domain of the c-e&-2 receptor protein (Langton et al., 1989) . The working antibody concentration was derived from the immunostaining of three human breast carcinomacell lines (SK-BR-3, m-75-1, and MCF-7). which are known to express the Tab #251-reactive moiety at high, moderate, and low levels, respectively. Cell lines were obtained from the American Type Culture Collection (Rockville. MD) and maintained as previously described (Kraus et al.? 1987) . As a negative control, normal mouse serum (NMuS) (Gibco; Grand Island, NY) was diluted 1:lOOO in PBS/2% BSA. Epithelial and tumor cell populations were identified by reactivity with the MAb cocktail AEl/AE3 (Boehringer Mannheim; Indianapolis, IN), diluted 1:500 in PBS/I%BSA. This cocktail reacts specifically with high and low molecular weight human epithelial cytokeratin. Reactive lymphoid cell populations that usually co-exist with breast cancer cells were identified by reaction with the MAb LCA, diluted 1:lOO in PBS/2%BSA (Dako; Santa Barbara, CA). LCA is directed against the CD45 leukocyte common antigen. To assess the tissue quality of each tumor sample, a standard Diff Quik stain (American Scientific Products: AHS de Caribe Aguoda, Puerto Rico) was prepared.
Tissue Preparation. Frozen tissue specimens were embedded in OCT Compound (Miles; Elkhart, IN) for thin sectioning in a cryostat microtome with a thermostat setting of -16'C. Sections 4 pm thick were cut and placed on gelatin/potvsium dichromate-coated slides. Sections were air-dried overnight at room temperature and acetone-fixed for 10 min at room temperature, followed by an additional 30 min of drying before initiation of the staining assay.
Immunohistochemical Assay. The IHC method used in this study is similar to a previously published technique, with a few modifications (Hsu et al., 1981) . Slides were rinsed three times in PBS for 5 min each (PBS wash), followed by an incubation for 15 min in 5 % normal hone serum (NHsS) diluted in PBS/2%BSA. The appropriately diluted primary antibody was then applied. Slides were incubated for 60 min at room temperature in a humidity chamber. Slides were then rinsed in PBS and subsequently incubated in the presence of the secondary antibody for 30 min at room temperature. The secondary antibody used was a biotinylated affinity-purified horse anti-mouse IgG (Vector; Burlingme, CA) used at a working dilution of 1:lOO in 2% BSA. Slides were rinsed in PBS, followed by a 30-min incubation in premixed Elite Universal Kit reagents as recommended by the product insert (Vector). The PBS wash was repeated and sections were developed in the enzyme substrate diaminobenzidine (DAB) solution (100 mg 3,3'-diaminobenzidine3 200 ml 0.05 M Tris buffer, pH 7.6, 2 ml 0.6% H202; Sigma, St Louis, MO). After chromogen development, slides were washed in running tap water for 10 min and counterstained with 1% methyl green (Sigma) in sodium acetate buffer. pH 5.2. Slides were then dehydrated, cleared in xylene, and mounted in permanent coverslipping media (Pro-TEXX; Bwter. McGaw Park. IL). DNA Analysis. Tissue fragments (0.3 g) were pulverized in liquid nitrogen and the DNA prepared by phenol extraction as described (Maniatis et al.. 1982) . Fifty micrograms of DNA were cleaved with the restriction endonudnx EcoRI according to recommended conditions (BRL; Bethesda, MD) . After digestion, DNA was denatured with 0.1 M sodium hydroxide and neutralized with 1.0 M ammonium acetate. Serial twofold dilutions of each sample were applied to replicate nitrocellulose filters using a dot-blot manifold. Hybridization was performed using a [ 32P]-dCTP labeled, nick-translated 1.6 KB EcoRI fragment of the human c-erbB-2 cDNA (Lambda MAC 30) (Kraus et al.. 1987) . A 2.9 KB genomic fragment ofc-mos served as a control for DNA amounts applied to replicate nitrocellulose filters (Kraus et al.. 1987) . Genomic DNA prepared from cultured cell lines (SK-BR-3. a-75-1, and MCF-7) containing previously determined c-erbB-2 gene copy numbers were used as controls for the presence of normal and amplified genes (Kraus et al., 1987) . All probes were kindly provided by Dr. Matthias Kraus (National Cancer Institute; Bethesda, MD). Hybridization was performed in 10 mM Tris buffer. pH 7.5, containing 50% formamide and 10% dextran sulfate, at 40'C for 14 hr. The membranes were then washed at high stringency in 0.1 x SSC (50 mM sodium citrate, 50 mM sodium chloride, and 0.1% sodium dodecylsulfate) at S O T for 20 min (Maniatis et al., 1982) . Autoradiography was performed using Kodak XR5 film with intensifying screens at -7O'C.
Immunoblotting (Western Blot). Tumor tissue was homogenized in hypotonic buffer (0.04 M Hepes, pH 7.4). The nuclear fraction was removed by centrifugation at 600 x g. Membranes were pelleted at 100.000 x g for 45 min and then solubilized in 0.02 M Hepes containing 0.05 M sodium chloride, 0.1% sodium dodecylsulfate, 0.1% Triton x-100, and 1% P-mercaptoethanol. Protein concentration was determined using the Bio-Rad Protein Assay Kit (Bio-Rad: Richmond, CA). Forty micrograms of each membrane preparation per lane were electrophoretically separated on 7% denaturing gels and transferred to nitrocellulose (Towbin et al., 1979) . The nitrocellulose was treated for 1 hr in Blotto solution (2% non-fat dry milk, 1% E t o n X-100, 50 mM ?iis-HCI, pH 7.4, and 10 mM E m ) and incubated in a mixture of two polyclonal rabbit antisera raised against peptides corresponding to amino acid positions 866-880 and 1242-1256 of the c-etbB-2 protein for 2 hr at room temperature. Antisera were kindly provided by Dr. Matthias Kraus. Blots were washed three times with Blotto solution and treated with 2 x 10' cpm/ml of [ '2'I]-protein A for 30 min at room temperature. The filters were again washed three times with Blotto solution. Detection was accomplished by autoradiography using Kodak XR5 at -7O'C. With the use of these two peptide antisera and the detection conditions specified. there was no crossreactivity with the epidermal growth factor receptor. The specificity of this antibody mixture has been previously described (Lacroix et al.. 1989) .
Results
Breast cancer specimens were collected fresh from the operating room from patients with all stages of disease. Seventy-one cases were analyzed by immunohistochemistry and dilutional DNA assays. Thirty-nine of these cases were also analyzed by Western immunoblotting for cell membrane overexpression of the c-erbB-2 oncoprotein.
A grading scale for interpretation of the IHC was established from the known immunoreactivity of cell lines SK-BR-3 (4+), ZR-75-1 ( 2 + ) , and MCF-7 ( I + ) and is defined as follows: I + , light brown membrane staining; 2 + , medium brown membrane with light cytoplasmic staining; 3 + , dark cell membrane and medium to dark cytoplasmic staining; 4 + , dark cell membrane and cytoplasmic staining with visual obstruction of the nucleus. IHC was evaluated by a single investigator UDI) in a blinded fashion. Fig  ure 1 shows representative tissue sections after reaction with MAb l i b #251. The incidence of oncoprotein expression as measured by relative staining intensity was determined as follows: 1 + , 22/71 (31%); 2 + , 20171 (28%); 3 + , 19/71 (27%); and4+, 10171 (14%). Overall, 2 9 (41%) of the 71 cases studied contained levels of immunoreactivity graded as either 3 + or 4 + in staining intensity. Gene copy number was determined in each case by sequential dilution of restriction enzyme-digested genomic DNA and hybridization to the c-erbB-2 probe. A c-mos gene probe was used as a reference. We have never observed amplification of the c-mosgene in human breast tissue. In all cases, Southern hybridization confirmed the results of the dot-blot analysis and revealed two bands of correct size after EcoRI digestion (data not shown). Gene amplification was present in 27 (38%) of the 71 cases studied. The majority of these amplified cases (17 of 27) contained between fourand eightfold amplification of the c-erbB-2 gene; seven cases contained a two-to fourfold amplification, and a greater than eightfold increase in gene number was measured in three cases.
For analysis of the c-erbB-2 receptor-like protein, solubilized membrane fractions were subjected to Western immunoblotting, or IHC was performed in tissue sections. Sufficient tissue was available in 39 tumor samples to allow determination of the c-er&-2 protein by both Western blotting and IHC and to perform analysis of gene content. As previously published, levels of the specific protein were determined by Western blotting after loading equivalent amounts of total membrane protein from the SK-BR-3 mammary carcinoma cell line which contains c-erbB-2 gene amplification (3 + to 4+). ZR-75-1 cells which overexpress both c-er&-2 mRNA and specific protein in the absence of gene amplification ( 2 +), and MCF7 cells which harbor neither increased c-er&?-2 protein nor gene copy number (1+) (9). Among the 39 tumors analyzed, 13 (33%) contained specific bands Comparable to SK-BR-3 and greater than ZR-75-1 (3+ to 4+). Twelve (31%) expressed more specific protein than MCF7 and comparable to a -7 5 -1 (2 +)$ and 14 (36%) expressed low levels of the receptor-like molecule with bands similar in intensity to MCF-7. Figure 3a (lane 3) . Western blot analysis of a tumor is shown in which the lane intensity is equal to MCF-7 cells (1 + ). However, IHC analysis of this tumor reveals moderate ( 2 +)staining intensity. Three such cases presented in Figure 2 were found in which the Western blot appeared to underestimate C-er6B-2 protein content. Conversely, four cases were found in which Western blot predicted moderate ( 2 + ) protein content but IHC revealed low-level (I+) staining. All cases except one contained a diploid c-er&?-2 gene equivalent. In four cases, shown at the bottom right of Figure 2 , the IHC staining was graded as 3 + to 4+; however, the intensity of the Western bands was either 1 + or 2 + . In two of these cases, only a small amount of tumor cells was present in the section used for IHC, as indicated by the subscript 6. The remainder of the section contained non-neoplastic stroma. In one case, containing a fourfold gene amplification. IHC correctly revealed intense overexpression of the c-erbB-2 product which was not corroborated by Western blot analysis. The other case presented in Figure 2 . bottom right, contained a twofold increase in gene copy number and was correctly determined to overexpress the c-er&-2 product by IHC analysis, but produced a band of only 1+ intensity by Western blot. It is likely that in these discrepancies sampling error in the choice of material digested for immunoblotting accounts for the false-negative Western results. In fact, two cases containing c-erbB-2 gene amplification and highlevel overexpression by IHC were not recognized by Western blot (solid circles, subscript U , Figure 2) .
To determine the relationship between expression and c-erbB-2 gene content, IHC and dilutional DNA hybridization were compared in all 71 cases (Figure 4 ). Of the 27 cases harboring amplifi- 
2.
3. 
4.

IMMUNOHISTOCHEMICAL STAINING INTENSITY
Relative
1 1 4 Amount noma that was stroma rich and tumor poor (subscript 6) reacted intensely with the c-erbB-2 antibody. An example of a pure intraductal carcinoma that was analyzed by both dilutional DNA hybridization and IHC is shown in Figure 5 . Figure Sa shows thc DNA dot-blot analysis and the method for calculation of the gene copy number; Figure 5b shows the corresponding IHC. By dilutional DNA analysis, this case is diploid with respect to genomic c-erbB.
2; however, the IHC reveals a high level of overcxprcssion usually seen in the presence of gene amplification. Again, sample selection could account for this discrcpancy.
In general, invasive tumors that contain a diploid cquivalent of the c-er6B-2 gene by aggregate measurement react wcakly or moderatcly with the c-er6B-2 antibody in IHC. The majority of tumors harboring gene amplification (89%) react intensely with c-erbB-2 antisera. Conversely, intense staining of mammary carcinoma accurately predicts the presence of an increase in c-erbB-2 gene copy Icvel. Exceptions to these trends may be explained by sampling error in techniques relying on extraction and aggregate measurement, particularly in intraductal or stroma-rich tumors.
Discussion
Amplification of the c-erbB-2 gene is an important prognostic factor in predicting disease-free and overall survival in breast canccr patients, although this is not without controvcrsy (Eble 1). In the 12 published reports reviewed in Tablc 1, seven performed Southern DNA analysis. Of these seven. five corroborated thc correlation of gene amplification with survival. One report found that gene amplification correlates with lymph node status, while only one found no significant corrclation bctwecn cither survival or lymph node status. In the remaining five revicwed reports, protein expression of c-erbB-2 was evaluated cithcr by Western immuno-1 1 '/ 2 Figure 5. Gene amplification of c-erb8-2 in human breast carcinomas. (a) Southern dot-blot analysis: lanes 1 and 2, MCF-7 cell line negative for c-erb8-2; lanes  3 and 4, patient sample; lanes 5 and 6, SK-BR-3 cell line positive for c-efb8-2. (b) A c-mos gene probe was used as a reference probe. (c) IHC assay for the  c-erb8-2 protein product on the same patient from lanes 3 and 4 in (a) . IHC denotes a strong staining pattern, while Southern dot-blot exhibits a normal gene copy number. Bars -100 rm. blotting or by IHC. In the one report where Western immunoblotting was performed, there was correlation in node-positive cancers with overexpression and diminished survival. In the four reports where IHC was performed, three of the four found either no correlation or correlation only within limited subsets. One additional study found protein overexpression to be an independent indicator of prognosis in both node-positive and node-negative cancers. Therefore, summarizing the 12 studies reviewed, amplification of the c-erbB-2 gene seems to be an important prognostic indicator in operable breast cancer. However, taking into account only the aforementioned data, protein overexpression of c-erbB-2 cannot be directly correlated with survival because of conflicting IHC results. These conflicting results may be due to inclusion of only certain stages of operable breast cancer, positive correlations confined only to certain subsets of patients, or the use of inadequate material.
The purpose of the present study was to assess the relationship of c-erbB-2 gene amplification and expression of the gene product in a series of carefully collected frozen breast tissues. The prognostic utility of either amplification or overexpression could not be specifically addressed. However, it was possible to relate status of the c-erbB-2 gene and the expression of the receptor protein determined by IHC and Western blot to pathological stage and to the number of histologically involved lymph nodes. Using the chi-square test of significance, there was a strong correlation between the pres-ence of gene amplification and categories of node positivity (0, 1 to 4, >4 histologically positive nodes). Gene amplification was more likely in tumors from patients with greater than four positive nodes (p = 0.007). In overall tests of significance, there was weak correlation between expression (1 + , 2 + , 3 + to 4 + ) measured by either IHC or immunoblotting and either stage or nodal involvement.
However, in comparing high-level overexpression (3 + to 4 + ) measured by both methods with low-or moderate-level expression, a correlation again was uncovered between nodal involvement and high-level overexpression. Although it appeared that IHC was at least as predictive as Western blot, the numbers of cases examined was too small to conclude that one or the other was more predictive. However, to the extent that high-level overexpression predicts the presence of gene amplification, expression may correlate with more advanced clinical stages if high-level expression is distinguished from moderate and low expression.
It is significant to recognize that in all four reports from Table  1 in which immunohistochemical analysis w1s carried out, archived formalin-fixed, paraffin-embedded material was employed. There are several disadvantages to use of paraffin tissues owing to many uncontrollable variables during processing: (a) the time lapse from excision to fixation; (b) the actual time that the tissue is in fixative; and (c) the variation in temperature of the embedding station from block to block and from technician to technician. All of these fac-tors have a direct impact on the quality of antigen preservation. Many other groups have documented heterogenous staining patterns when using paraffinized tissue (Slamon et al., 1989; Wright et al., 1989; Barnes et al., 1988; Berger et al., 1988; van de Vijver et al., 1988) . By utilizing fresh-frozen tissue for evaluation of the c-erbB-2 protein product, processing artifacts can be minimized. In addition, the use of fresh tissue in the IHC assay allows direct visualization of the tissue being studied. This has several advantages, including: (a) verification before analysis that there is tumor in the sample; (b) recognition of those tumors with abundant stroma and necrosis; and (c) identification of the histology of cancers that are purely intraductal vs those that are infiltrating with a ductal component. In the case of the latter, the two components can now be studied and interpreted separately.
In the study presented here, the relationship between expression of the c-erbB-2 protein and status of the gene was investigated in operable breast cancer. Seventy-one fresh samples were randomly collected and analyzed by Southem DNA hybridization for c-erbB-2 gene copy number. Protein expression was assessed using Western immunoblotting (39 cases), which is an aggregate measurement of an enriched membrane preparation, and by IHC (71 cases), which allows direct visualization and assessment of the individual cells within the tissue. By Southern analysis, 27 (38%) of 71 cases contained a twofold or greater increase in gene copy number of c-erbB-2. The frequency of gene amplification observed in this group of tumors is similar to estimates from other series (Lacrok et al., 1989; Slamon et al., 1989; Berger et al., 1988; van de Vijver et al., 1988; Varley et al., 1987; Zhou et al., 1987) . High-level overexpression (3+ to 4 + ) was observed in 24 (89%) of these 27 amplified tumors as assessed by IHC. A smaller number of cases were examined by Westem immunoblotting, but again the majority of amplified cases (10 of 13) expressed high levels of the c-erbB-2 protein product. Interestingly, IHC was performed on those three cases which were not overexpressing the c-erbB-2 protein as assessed by Western immunoblotting, but were amplified by Southern hybridization. In these cases, IHC demonstrated high levels of oncoprotein overexpression. The apparent enhanced sensitivity of IHC over Western blotting is suggested by the histological assessment of these particular tumor samples. Histologically, these tissues were stroma rich, with a minority of tissue bearing neoplastic cells. In such cases, it is likely that the non-neoplastic cell components of the "tumor" sample may dilute, and therefore overrepresent, neoplastic elements in the Westem blot technique. As such, the detection of oncoprotein overexpression may fall at or below the sensitivity of the assay, or to ranges within low levels of expression. In general, c-erbB-2 gene amplification usually results in detection of high-level overexpression of the protein product by either Western blot or by IHC. These observations agree with similar data from other reported series (Lacrok et al., 1989; Slamon et al., 1989; Berger et al., 1988; Venter et al., 1987) . On the other hand, IHC may offer specific advantages over immunoblotring in selected cases where histological verification of tumor or tumor availability within the specimen (intraductal disease, tumor poor, or stroma rich) is limited.
High-level overexpression is rarely observed in tumors harboring normal c-erbB-2 gene content. Of 43 tumors with normal c-erbB-2 gene number, 21 expressed low levels (1 + ), 17 expressed moderate (2 + ) levels, and five cases expressed high levels (3 + to 4 + ) of c-erbB-2 protein (Figure 4) . Of the latter five cases, four involved purely intraductal tumors which were highly expressing the c-erbB-2 oncoprotein. The remaining case involved a specimen containing a paucity of neoplastic elements. In these cases, aggregate DNA extracted for Southern hybridization would contain a minor fraction of tumor-derived DNA. As such, the c-erbB-2 gene copy number may well be diluted to non-amplified levels by the relatively abundant normal cell components. On the other hand, the presence of high-level expression in the intraductal component of breast cancer has been observed previously (Lacroix et al., 1989; Slamon et al., 1989; Berger et al., 1988; van de Vijver et al., 1987; Varley et al., 1987; Zhou et al., 1987) , however, and the mechanism of this high expression is not yet determined. An intermediate category of moderate expression from single-copy genes has also been reported in mammary cancer cell lines (Kraus et al., 1987) and in tissue (Thor et al., 1989; van de Viver et al., 1989; Wright et al., 1989; Barnes et al., 1988) . The significance of overexpression, in the absence of gene amplification, both to the initiation of breast cancer and to its behavior has not been specifically investigated. IHC appears capable of discriminating both moderate levels (2 + ) and high levels (3 + to 4 + ) of expression in the absence of c-erbB-2 gene amplification.
In conclusion, the accuracy of Southern DNA hybridization and Western immunoblotting for the estimation of c-erbB-2 gene amplification and its protein expression appears to be highly dependent on adequate tumor mass within assayed specimens. Often an uncontrolled variable in extraction techniques, IHC allows the direct in situ visualization of the cell components within a tumor specimen. As shown, IHC corroborates c-erbB-2 gene amplification and protein expression in the majority of cases. In exceptional cases of limited disease, such as biopsy specimens, stroma-rich tumors, or intraductal lesions, IHC offers distinct analytical advantages over extraction techniques through enhanced sensitivity. As such, IHC offers a favorable alternative to either Southern hybridization or Western immunoblotting in the assessment of c-crbB-2 gene copy number and expression levels of the oncoprotein in human mammary carcinoma.
